Floatz logo

f182112

Relapsed or Refractory Multiple Myeloma (RRMM)

Shandong New Time Pharmaceutical Co., LTDPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

497 Active assets in the Relapsed or Refractory Multiple Myeloma (RRMM) cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

f182112 is also rated in:

plasma cell myelomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →